http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Aucubin 의 Ribonucleic Acid 생합성 억제작용
장일무,박영춘,윤혜숙 ( Il Moo Chang,Young Choon Park,Hye Sook Yun ( Choi ) ) 생화학분자생물학회 1982 BMB Reports Vol.15 No.3
Aucubin, an iridoid gludoside, was isolated from Aucuba japonica (Cornaeae). One of biological activities of aucubin was found to inhibit RNA biosynthesis in leukemia SN 36 tumor cells in vitro. Aucubin appeared not to possess antitumor activities against leukemia SN 36 murine tumor. The combination therapy with aucubin plus actinomycin D did not show any significant additive or synergistic antitumor activities in comparison with that of actinomycin D alone treatment.
장일무,Chang, Il-Moo 생화학분자생물학회 1975 한국생화학회지 Vol.8 No.1
Adenosine, 6-methylthioinosine, 및 6-methylthioinosine-3', 5'-cyclic monophosphate가 PRPP amidotransferase 효소 작용을 방해하여 de novo purine 생합성에 미치는 영향을 관찰하였다. $10^{-3}M$부터 $10^{-5}M$까지의 농도변화에서 adenosine이 de novo purine 생합성을 저지하는 정도는 약 10% 차이를 갖고 즉 70~80% 정도를 억제하였는데 MTI나 c-MTIMP는 $10^{-3}M$에서는 약 90%의 de novo purine 생합성을 억제한데 반하여, $10^{-3}M$ 이하의 농도에서는 de novo purine 생합성 억제 정도가 신속히 저하되었다. $10^{-3}M$ 농도에서 MTI나 c-MTIMP가 L 1210 암 세포의 DNA 또는 RNA 생합성을 억제하는 정도는 de novo purine 생합성을 억제하는 정도보다 훨씬 낮음이 관찰되었다. Adenosine, 6-methylthioinosine and 6-methylthioinosine-3', 5'-cyclic monophosphate exhibit feedback inhibition of PRPP amidotransferase. In order to obtain the relative potencies of three drugs, the concentration curves were made in range from $10^{-3}M$ to $10^{-5}M$. The potency of feedback inhibition by adenosine decreased by about 10%, whereas inhibition by MTI or c-MTIMP was decreased markedly at lower than $10^{-3}M$. At $10^{-3}M$, MTI or c-MTIMP appeared to inhibit about 90% of de novo purine biosynthesis, but the degree of inhibition of DNA and RNA in L 1210 cells by MTI and c-MTIMP at $10^{-3}M$ appeared to be lower than those of de novo purine biosynthesis.
Rhodium(II) Acetate와 1-$\beta$-D-Arabinosyl Cytosine과의 병용 투여시 Leukemia 1210 Tumor에 대한 항암작용의 상승효과
장일무,Chang, Il-Moo 생화학분자생물학회 1975 한국생화학회지 Vol.8 No.1
rhodium(II) acetate 단독으로 또는 arabinosyl cytosine (ara-C)와 병영 투여하였을 경우 이들 물질이 leukemia 동물암 모델인 leukemia 1210을 복강에 이식시킨 $BDF_1$, mice에 나타내는 항암작용을 관찰하였다. rhodium acetate 단독투여시 이 물질의 항암작용은 거의 나타나지 않았으나 rhodium(II) acetate와 ara-C와의 병용투여시는의 의있는 항암작용의 상승효과를 관찰할 수 있었다. rhodium(II) carboxylate 중 rhodium(II) acetate, rhodium(II) propionate 및 rhodium(II) methoxyacetate는 deoxycytidine deaminase의 효소작용인 deamination을 크게 방해했음을 관찰했으며, 이러한 deamination을 방해 하는 작용은 rhodium(II) acetate와 ara-C의 병용투여시 항암작용의 상승효과를 일으키는 하나의 원인이 될 수 있을 것이다. The studies involved the treatment of $BDF_1$ mice bearing leukemia 1210 tumor with rhodium(II) acetate and rhodium(II) acetate in combination with arabinosyl cytosine (Ara-C). Rhodium(II) acetate alone showed no significant antitumor activity. However, the combination of rhodium(II) acetate and ara-C under the particular dose-schedules exhibited potent synergistc effects in treatment of $BDF_1$ mice bearing leukemia 1210 tumor. Rhodium(II) acetate, rhodium(II) propionate and rhodium(II) methoxyacetate appeared to inhibit the activity of deoxycytidine deaminase. The inhibition of deoxycytidine deaminase by rhodium(II) carboxylates possibly contributes some part of the synergistic effects to the combination therapy with rhodium(II) acetate and ara-C.
Inhibition of Ribonucleic Acid Biosynthesis in Leukemia SN 36 Cells in vitro by Aucubin
장일무,박영춘,윤혜숙,Chang, Il-Moo,Park, Young-Choon,YunChoi, Hye-Sook 생화학분자생물학회 1982 한국생화학회지 Vol.15 No.3
Aucubin, an iridoid gludoside, was isolated from Aucuba japonica(Cornaeae). One of biological activities of aucubin was found to inhibit RNA biosynthesis in leukemia SN 36 tumor cells in vitro. Aucubin appeared not to possess antitumor activities against leukemia SN 36 murine tumor. The combination therapy with aucubin plus actinomycin D did not show any significant additive or synergistic antitumor activities in comparison with that of actinomycin D alone treatment. Iridoid glucoside인 aucubin을 식나무, Aucuba japonica(Cornaceae)로 부터 순수분리하였다. 이 물질의 약리작용을 밝히기 위하여 동물암 세포인 leukemia SN 36 세포의 RNA 생합성에 미치는 영향을 조사한 결과, 농도 0.5 mM 및 1.0 mM에서 각각 30% 및 46% 정도의 RNA 생합성 억제작용을 aucubin은 갖고 있음을 알 수 있었다. Aucubin 자체는 동물암인 leukemia SN 36에 큰 항암작용을 나타내지는 못하였고, Actinomycin D와 병용투여시에도 additive 또는 synergistic 효과 역시 나타내지는 않았다.
Rhodium ( Ⅱ ) 2 ( Propionate ) 2 L4 가 Ehrlich 암세포 분열에 미치는 영향
장일무,우원식 ( Il Moo Chang,Won Sick Woo ) 생화학분자생물학회 1976 BMB Reports Vol.9 No.3
Rhodium(II)₂ (propionte)₄ L₂ is one of few metalic compounds to exhibit antitumor activity against murine tumors. It was demonstrated that 2.7 ㎎/㎏ of rhodium (II)₂ (propionate)₄ L₂ inhibited DNA synthesis of Ehrlich tumor cells in vivo, whereas 0.3㎎/㎏ of this ccmpound did not. Autoradiographic studies indicated that rhodium(II)₂ (propionate)₄L₂ caused disruption of the cyclic pattern of Ehrlich tumor cell replication. It was observed that rhodium(II)₂ propionate₄L₂ exhibited marked reduction in mitotic indices of Ehrlich tumor cells. Ehrlich tumor cells in G₂ phase appeared to be sensitive to rhodium (II)₂ (propionate)₄ L₂.
장일무(Il-Moo Chang),김영수(Young-Soo. Kim),한병훈(Byung-Hoon Han) 한국생약학회 1982 생약학회지 Vol.13 No.1
Potential toxicity of 15 medicinal plants used for herbal drugs, which were also described as being tonic for hematopoietic system or being toxic for the system in a oriental book Dong Ee Bo Gam, were evaluated in mice. Six plants among 15 plants tested appeared to exhibit acute toxicity along with bone marrow depression or with abnormally enhancing the ³H-thymidine incorporation into DNA biosynthesis in bone marrow cells. Six plants were Paeonia albiflora, Pharbitis nil, Cemphalia lapidescens, Scutellaria baicalensis, Akebia quinata and Glycyrriza uralensis.
장일무(Il-Moo Chang),지형준(Hyung-Joon Chi) 한국생약학회 1981 생약학회지 Vol.12 No.3
Thirty species of Korean medicinal plants which have been frequently used in Oriental herb prescriptions were evaluated on their acute toxicity and potential antitumor activities against P-388 lymphocytic leukemia. The criteria for toxicity evaluation of measuring weight loss, toxicity day survivors and computing log cell kill indicated that 11 species possessed acute toxicity according to the doses administered. No significant antitumor activities were observed while the root of Angelica gigas Nakai (Umbelliferae) exhibited only 24% increased life span.
한국산생약의 독성연구 (Ⅱ) : 조혈기관에 미치는 영향
장일무(Il-Moo Chang),김영수(Young-Soo Kim),장경숙(Keong-sug Chang),한병훈(Byung-Hoon Han) 한국생약학회 1982 생약학회지 Vol.13 No.1
생약 15종을 선정하여 이들의 독성을 조사하였으며 (1) 급성독성으로써 체중감소여부, (2)조혈기관중 골수세포(bone marrow)의 디옥시리보핵산 생합성 (DNA biosynthesis) 정도 및 헤모그로빈양을 측정하였다. 디옥시리보핵산 생합성정도는 ³H-thymidine의 골수세포 도입량으로 추정하였다. 15종의 생약엑기스를 4일간 경구투여 (600㎎/㎏, 400㎎/㎏, 200㎎/㎏)하였으며, 체중은 매일 디옥시티보핵산 생합성 및 헤모그로빈양 측정은 7일째 실시하였다. 체중이 현저히 감소한 것은 견우 자, 적작약, 뇌환 등이며 Hb number에 있어 현저한 감소가 있는 것은 적작약, 새신 등이며, DNA 생합성이 현저히 감소한 것은 적작약, 뇌환, 치전자등이다.
Il-Moo Chang(장일무),Hye Sook Yun(윤혜숙),Kazuo Yamasaki(야마사끼 가즈오) 한국생약학회 1981 생약학회지 Vol.12 No.1
β-Sitosteryl-3-O-β-D-glucopyranoside was isolated from the seeds of Plantago asiatica(Plantaginaceae). The assignments of <sup>13</sup>C NMR spectra of β-sitosterol and β-sitosteryl-3-O-β-D-glucopyranoside were made by comparing with <sup>13</sup>C NMR spectra of cholesterol and cholesteryl-3-O-β-D-glucopyranoside. Our data indicate that the revision of previous ^(l3)C NMR spectral assignment is needed.
장일무 ( Il Moo Chang ) 생화학분자생물학회 1975 BMB Reports Vol.8 No.1
The studies involved the treatment of BDF₁ mice bearing leukemia 1210 tumor with rhodium (II) acetate and rhodium (II) acetate in combination with arabinosyl cytosine (Ara-C). Rhodium (II) acetate alone showed no significant antitumor activity. However, the combination of rhodium (II) acetate and ara-C under the particular dose-schedules exhibited potent synergistc effects in treatment of BDF₁ mice bearing leukemia 1210 tumor. Rhodium (II) acetate, rhodium (II) propionate and rhodium (II) methoxyacetate appeared to inhibit the activity of deoxycytidine deaminase. The inhibition of deoxycytidine deaminase by rhodium (II) carboxylates possibly contributes some part of the synergistic effects to the combination therapy with rhodium (II) acetate and ara-C.